Literature DB >> 27142126

Kidney cancer: VEGFR-TKI after anti-PD-1 therapy is safe.

Louise Stone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27142126     DOI： 10.1038/nrurol.2016.79

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.

Authors:  R Nadal; A Amin; D M Geynisman; M H Voss; M Weinstock; J Doyle; Z Zhang; A Viudez; E R Plimack; D F McDermott; R Motzer; B Rini; H J Hammers
Journal:  Ann Oncol       Date:  2016-04-07       Impact factor: 32.976
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.